SARS-CoV-2 Variants in Rhode Island; May 2022 Update.


Journal

Rhode Island medical journal (2013)
ISSN: 2327-2228
Titre abrégé: R I Med J (2013)
Pays: United States
ID NLM: 101605827

Informations de publication

Date de publication:
01 Aug 2022
Historique:
entrez: 14 7 2022
pubmed: 15 7 2022
medline: 19 7 2022
Statut: epublish

Résumé

Genomic surveillance allows identification of circulating SARS-CoV-2 variants. We provide an update on the evolution of SARS-CoV-2 in Rhode Island (RI). All publicly available SARS-CoV-2 RI sequences were retrieved from https://www.gisaid.org. Genomic analyses were conducted to identify variants of concern (VOC), variants being monitored (VBM), or non-VOC/non-VBM, and investigate their evolution. Overall, 17,340 SARS-CoV-2 RI sequences were available between 2/2020-5/2022 across five (globally recognized) major waves, including 1,462 (8%) sequences from 36 non-VOC/non-VBM until 5/2021; 10,565 (61%) sequences from 8 VBM between 5/2021-12/2021, most commonly Delta; and 5,313 (31%) sequences from the VOC Omicron from 12/2021 onwards. Genomic analyses demonstrated 71 Delta and 44 Omicron sub-lineages, with occurrence of variant-defining mutations in other variants. Statewide SARS-CoV-2 genomic surveillance allows for continued characterization of circulating variants and monitoring of viral evolution, which inform the local health force and guide public health on mitigation efforts against COVID-19.

Sections du résumé

BACKGROUND BACKGROUND
Genomic surveillance allows identification of circulating SARS-CoV-2 variants. We provide an update on the evolution of SARS-CoV-2 in Rhode Island (RI).
METHODS METHODS
All publicly available SARS-CoV-2 RI sequences were retrieved from https://www.gisaid.org. Genomic analyses were conducted to identify variants of concern (VOC), variants being monitored (VBM), or non-VOC/non-VBM, and investigate their evolution.
RESULTS RESULTS
Overall, 17,340 SARS-CoV-2 RI sequences were available between 2/2020-5/2022 across five (globally recognized) major waves, including 1,462 (8%) sequences from 36 non-VOC/non-VBM until 5/2021; 10,565 (61%) sequences from 8 VBM between 5/2021-12/2021, most commonly Delta; and 5,313 (31%) sequences from the VOC Omicron from 12/2021 onwards. Genomic analyses demonstrated 71 Delta and 44 Omicron sub-lineages, with occurrence of variant-defining mutations in other variants.
CONCLUSION CONCLUSIONS
Statewide SARS-CoV-2 genomic surveillance allows for continued characterization of circulating variants and monitoring of viral evolution, which inform the local health force and guide public health on mitigation efforts against COVID-19.

Identifiants

pubmed: 35834172

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6-11

Auteurs

Manjot Singh (M)

Warren Alpert Medical School, Brown University, Providence, RI.

Vladimir Novitsky (V)

Warren Alpert Medical School, Brown University, Providence, RI.

Kristin Carpenter-Azevedo (K)

Rhode Island Department of Health State Health Laboratories, Providence, R.

Mark Howison (M)

Research Improving People's Life, Providence, RI.

Richard C Huard (RC)

Rhode Island Department of Health State Health Laboratories, Providence, RI.

Ewa King (E)

Rhode Island Department of Health State Health Laboratories, Providence, RI.

Rami Kantor (R)

Warren Alpert Medical School, Brown University, Providence, RI.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH